Spelling suggestions: "subject:"replacement astherapy"" "subject:"replacement 20therapy""
141 |
"They Need Labels": Contemporary Institutional and Popular Frameworks for Gender VarianceBradley, Ophelia 21 April 2010 (has links)
This study addresses the complex issues of etiology and conceptualization of gender variance in the modern West. By analyzing medical, psychological, and popular approaches to gender variance, I demonstrate the highly political nature of each of these paradigms and how gender variant individuals engage with these discourses in the elaboration of their own gender identities. I focus on the role of institutional authority in shaping popular ideas about gender variance and the relationship of gender variant individuals who seek medical intervention towards the systems that regulate their care. Also relevant are the tensions between those who view gender variance as an expression of an essential cross-sex gender (as in traditional transsexual narrative) and those who believe that gender is socially constructed and non-binary. I finally argue that the standards of treatment for gender variant individuals pertains more to the medical legitimization of their identities than with necessarily improving outcomes.
|
142 |
Prognose von Patienten mit Alport-Syndrom unter Berücksichtigung einer medikamentösen Intervention und verschiedener Nierenersatzverfahren / Prognosis of patients with aport syndrome considering a medical intervention and different renal replacement therapyAssmann, Angela 21 January 2015 (has links)
No description available.
|
143 |
Correlates of Episodic Memory Functioning in Older and Younger AdultsMaria Cabral Collerson Unknown Date (has links)
Abstract This study examined memory functioning from a female perspective, with the aim of determining factors that might impact performance and render the accuracy of memory measurement, particularly with advancing age, problematic. Factors investigated, among others, were the role of attention and/or engagement with the memory tasks administered, state affect (i.e., positive and negative arousal) at time of testing, subjective memory appraisal, particularly in the domain of perceived memory self-efficacy (MSE), and the use of hormone replacement therapy (HRT) by older post-menopausal women. Two experimental computer-based tests of episodic memory, Paired Associates (PA) and Serial Recall (SR), were administered to 181 female participants aged 18 to 86 years. The tasks were designed to emphasise components that make episodic memory especially difficult, and minimise the use of strategies that might assist recall. Thus, they varied the requirement for recall as opposed to recognition, the need to form an association between a pair of unrelated words, and the need to discriminate the most recent list from earlier list(s). Other measures used included a demographic survey administered to participants individually in an interview format, and a number of variables examined in this study derived from responses to items contained in this survey. The research battery also included psychometric measures of transient affective states, psychological well-being, alertness, in addition to measures of global cognitive status and metamemory (i.e., subjective memory appraisal). The overall aim was to examine a range of factors that might influence episodic memory performance in cognitively intact healthy women, and thus render the interpretation of age-related changes to memory functioning problematic. For analyses participants were assigned to three groups - young, middle-aged and older. There were 60 young adults aged 18 to 29 years, 60 middle-aged adults aged 49 to 60 years, and 61 older adults aged 61 to 86 years. Each participant was tested individually in a single session lasting approximately 3 ½ hours, with younger participants requiring less time to complete assessments. Order of test administration and instructions were standardised across the entire sample. Inferential statistics included correlation, t-test statistic, and analysis of variance (ANOVA) with Tukey post-hoc comparisons. Hierarchical multiple regression analyses were conducted to determine key correlates of memory performance outcomes. No significant differences between the cohorts were found in mean years of education. However, episodic memory recall differed significantly by age group. As expected, young adults recalled significantly more words in the memory tasks than their older counterparts, and middle-aged adults outperformed adults in the oldest cohort. Moreover, older adults’ performance deficits were more pronounced in the tasks requiring that they make an association between a pair of unrelated words. Across all cases, transient mood states were significantly related to memory scores; however, individuals in the oldest cohort were particularly vulnerable to mood fluctuations. This cohort experienced a significantly greater decline in positive affect and a significant greater increase in negative affect while undergoing memory testing, highlighting their greater vulnerability to stressors inherent in a memory testing situation. Although scores on the measure of attention were near ceiling, indicative of participants’ level of effort, motivation, and engagement with the memory tasks, the measure of attention discriminated between older and younger adults’ results, and was a key predictor of memory performance. Noteworthy is that attention scores significantly contributed to performance variability in younger and older adults but not in middle-aged adults. Across all cases, age, education, and attention were the key contributing factors to variability in memory scores. Although four lifestyle factors: (1) subjective sleep appraisal, (2) body mass index (BMI), (3) physical activity, and (4) caffeine intake were significantly associated with performance in the memory tasks, once the effects of these key variables were removed, lifestyle factor did not uniquely contribute to performance variability. Moreover, no association was found between hormone replacement therapy (HRT) and episodic memory performance across the broader sample. However, in a small subgroup of older women (n = 15, M age = 66 years), long-term users of this treatment, HRT had a significant effect on memory performance and was indicative of better recall on the memory tasks. The effect of subjective memory appraisal, MSE included, on objective performance outcomes was examined. The results showed that memory self-evaluations were not a significant contributing factor to episodic memory performance, confirming that memory self-appraisal is a poor predictor of actual memory performance, and thus does not pose a challenge to the measurement of age-related changes to memory abilities. Although there were commonalities, factors influencing memory performance differed by age cohort. For example, in young adults, positive mood, a perception of sleeping well, subjective health, and attention were significantly related to performance on the memory tasks. However, once the effect of attention was removed in the regression analysis, no other variable was predictive of episodic memory functioning in this cohort. In contrast, the single significant predictor of memory performance in middle-aged individuals was education, and neither attention, nor positive mood, or physical activity had a significant effect on this cohort’s performance. Similarly, having more years of formal education benefited older adults’ episodic memory functioning. However, high scores on global cognitive functioning and on the tasks measuring attention were equally important to episodic memory recall in this age group. In sum, the significant contribution of age to memory variability attested to the utility of the memory measures in detecting age-related changes to episodic memory functioning, which were independent of deficits in attention or level of education. Moreover, the effect of several factors (e.g., transient mood, lifestyle) on memory scores was explained by an effect on attention, and this has clear implication for the proper evaluation of long-term changes to memory functioning. Limitations of the study and suggestion for future research are discussed.
|
144 |
Correlates of Episodic Memory Functioning in Older and Younger AdultsMaria Cabral Collerson Unknown Date (has links)
Abstract This study examined memory functioning from a female perspective, with the aim of determining factors that might impact performance and render the accuracy of memory measurement, particularly with advancing age, problematic. Factors investigated, among others, were the role of attention and/or engagement with the memory tasks administered, state affect (i.e., positive and negative arousal) at time of testing, subjective memory appraisal, particularly in the domain of perceived memory self-efficacy (MSE), and the use of hormone replacement therapy (HRT) by older post-menopausal women. Two experimental computer-based tests of episodic memory, Paired Associates (PA) and Serial Recall (SR), were administered to 181 female participants aged 18 to 86 years. The tasks were designed to emphasise components that make episodic memory especially difficult, and minimise the use of strategies that might assist recall. Thus, they varied the requirement for recall as opposed to recognition, the need to form an association between a pair of unrelated words, and the need to discriminate the most recent list from earlier list(s). Other measures used included a demographic survey administered to participants individually in an interview format, and a number of variables examined in this study derived from responses to items contained in this survey. The research battery also included psychometric measures of transient affective states, psychological well-being, alertness, in addition to measures of global cognitive status and metamemory (i.e., subjective memory appraisal). The overall aim was to examine a range of factors that might influence episodic memory performance in cognitively intact healthy women, and thus render the interpretation of age-related changes to memory functioning problematic. For analyses participants were assigned to three groups - young, middle-aged and older. There were 60 young adults aged 18 to 29 years, 60 middle-aged adults aged 49 to 60 years, and 61 older adults aged 61 to 86 years. Each participant was tested individually in a single session lasting approximately 3 ½ hours, with younger participants requiring less time to complete assessments. Order of test administration and instructions were standardised across the entire sample. Inferential statistics included correlation, t-test statistic, and analysis of variance (ANOVA) with Tukey post-hoc comparisons. Hierarchical multiple regression analyses were conducted to determine key correlates of memory performance outcomes. No significant differences between the cohorts were found in mean years of education. However, episodic memory recall differed significantly by age group. As expected, young adults recalled significantly more words in the memory tasks than their older counterparts, and middle-aged adults outperformed adults in the oldest cohort. Moreover, older adults’ performance deficits were more pronounced in the tasks requiring that they make an association between a pair of unrelated words. Across all cases, transient mood states were significantly related to memory scores; however, individuals in the oldest cohort were particularly vulnerable to mood fluctuations. This cohort experienced a significantly greater decline in positive affect and a significant greater increase in negative affect while undergoing memory testing, highlighting their greater vulnerability to stressors inherent in a memory testing situation. Although scores on the measure of attention were near ceiling, indicative of participants’ level of effort, motivation, and engagement with the memory tasks, the measure of attention discriminated between older and younger adults’ results, and was a key predictor of memory performance. Noteworthy is that attention scores significantly contributed to performance variability in younger and older adults but not in middle-aged adults. Across all cases, age, education, and attention were the key contributing factors to variability in memory scores. Although four lifestyle factors: (1) subjective sleep appraisal, (2) body mass index (BMI), (3) physical activity, and (4) caffeine intake were significantly associated with performance in the memory tasks, once the effects of these key variables were removed, lifestyle factor did not uniquely contribute to performance variability. Moreover, no association was found between hormone replacement therapy (HRT) and episodic memory performance across the broader sample. However, in a small subgroup of older women (n = 15, M age = 66 years), long-term users of this treatment, HRT had a significant effect on memory performance and was indicative of better recall on the memory tasks. The effect of subjective memory appraisal, MSE included, on objective performance outcomes was examined. The results showed that memory self-evaluations were not a significant contributing factor to episodic memory performance, confirming that memory self-appraisal is a poor predictor of actual memory performance, and thus does not pose a challenge to the measurement of age-related changes to memory abilities. Although there were commonalities, factors influencing memory performance differed by age cohort. For example, in young adults, positive mood, a perception of sleeping well, subjective health, and attention were significantly related to performance on the memory tasks. However, once the effect of attention was removed in the regression analysis, no other variable was predictive of episodic memory functioning in this cohort. In contrast, the single significant predictor of memory performance in middle-aged individuals was education, and neither attention, nor positive mood, or physical activity had a significant effect on this cohort’s performance. Similarly, having more years of formal education benefited older adults’ episodic memory functioning. However, high scores on global cognitive functioning and on the tasks measuring attention were equally important to episodic memory recall in this age group. In sum, the significant contribution of age to memory variability attested to the utility of the memory measures in detecting age-related changes to episodic memory functioning, which were independent of deficits in attention or level of education. Moreover, the effect of several factors (e.g., transient mood, lifestyle) on memory scores was explained by an effect on attention, and this has clear implication for the proper evaluation of long-term changes to memory functioning. Limitations of the study and suggestion for future research are discussed.
|
145 |
Reproductive history and sex hormones and their association with subclinical atherosclerosis in women with and without type 1 diabetes /Snell-Bergeon, Janet K. January 2007 (has links)
Thesis (Ph.D. in Epidemiology) -- University of Colorado Denver, 2007. / Typescript. Includes bibliographical references (leaves 100-117). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;
|
146 |
Cardiovascular risk factor prevalence, mortality and cardiovascular disease incidence in patients who initiated renal replacement therapy in childhood : systematic review and analyses of two renal registriesGaliyeva, Dinara January 2017 (has links)
Background. The incidence of starting renal replacement therapy (RRT) among young people (< 20 years of age) in 2013 in Scotland was 7.7 per million (age-related) population. Little knowledge exists about cardiovascular risk factors (CVRFs), long-term survival and cardiovascular disease (CVD) outcomes in patients who initiated RRT in childhood. The main source of routine data for these patients is available from the European Society of Paediatric Nephrology/European Renal Association- European Dialysis and Transplant Association (ESPN/ERA-EDTA) registry. In Scotland nationally comprehensive data on patients receiving RRT is available from the Scottish Renal Registry (SRR). Aim and objectives. The overall aim of the thesis is to review relevant literature and conduct retrospective cohort studies describing CVRF prevalence, all-cause mortality and incidence of CVD outcomes in patients who initiated RRT in childhood. ESPN/ERA-EDTA registry data were used to describe the prevalence of anaemia, hypertension, dyslipidaemia and BMI categories and their association with all-cause and CV mortality. SRR data were used to describe all-cause mortality and CVD incidence and their association with age at start of RRT, sex, primary renal disease (PRD), type of RRT and period of start of RRT. Methods. Systematic searches were performed to identify relevant literature. For the ESPN/ERA-EDTA analyses patients who started RRT between 0 and 20 years of age and who had CVRF data were included. Patients were followed from date of first CVRF measurement until the earliest of death, loss to follow-up, reaching 20 years of age or the end of follow-up (December 31st 2012). Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for mortality, comparing patients with and without each CVRF. For the SRR analyses, patients who started RRT under 18 years of age in the period from 1963 to 2013 were included in the analyses. To describe CVD incidence the SRR data were linked to national registers for death and CVD hospital admissions available from 1981 onwards. These analyses, therefore, included patients who started RRT between 1981 and 2013 with follow-up until first CVD event after start of RRT, end of follow-up period or censoring at death. Cox proportional hazard models were used to examine the association of age at initiation of RRT, sex, PRD, type of RRT and period of initiation of RRT with all-cause mortality and CVD incidence. Results. The systematic reviews revealed a gap in current knowledge about CVD incidence and the association of CVRFs with CVD outcomes in patients who initiated RRT in childhood. In total, 7,845 patients were included in the ESPN/ERA-EDTA registry analysis. The mean age of the patients was 9.5 (SE 0.06) years, 58.9% were male, and the most common PRD was congenital anomalies of kidney and urinary tract (CAKUT). The prevalence of dyslipidaemia, hypertension, anaemia overweight/obesity and underweight was 87.5%, 79.3%, 36.0%, 29.9% and 4.3%, respectively. During median follow-up of 3.7 (IQR 1.7-6.8) years 357 patients died. HRs for anaemia were 2.19 (95% CI 1.64-2.93) and 2.55 (95% CI 1.27-5.12) for all-cause and CVD mortality, respectively. The HR for all-cause mortality for underweight was 1.81 (95% CI 1.30-2.53). No other studied CVRFs were statistically significantly associated with all-cause and CVD mortality. In total, 479 patients were included in the SRR analyses of all-cause mortality. The most common PRD was CAKUT and 55.3% of patients were male. During a median follow-up of 18.3 (IQR 8.7-27.0 years) years 126 patients died. Twenty-year survival among patients initiated RRT in childhood was 77.6% (95% CI 73.8-81.3). Age at start of RRT, PRD and type of RRT were significantly associated with all-cause mortality. HR for all-cause mortality for patients who started RRT under 2 years of age was 2.50 (95% CI 1.19-5.25) compared to patients who started RRT at 12 to 18 years old. HR for all-cause mortality for patients with PRD other than CAKUT or glomerulonephritis (GN) was 1.58 (95% CI 1.05-2.39) compared to patients with CAKUT. HRs for all-cause mortality for patients who only received either HD or PD during follow-up were 19.4 (95% CI 10.4-36.4 and 19.5 (9.65-39.7), respectively, compared to patients who received a renal transplant. In total, 381 patients were included in the SRR analyses of CVD incidence. During a median of 12.9 (IQR 5.6-21.5) years of follow-up after initiation of RRT 134 patients (35.2%) developed CVD. The overall crude CVD incidence was 2.6 (95% CI 2.2-3.0) per 100 person-years. HRs for CVD were 1.69 (95% CI 1.05-2.74) for males compared to females, 1.72 (95% CI 1.02-2.91) for PRD other than CAKUT or GN compared to CAKUT and 8.38 (95% CI 3.31-21.23) and 7.30 (95% CI 2.30-23.16) for patients who only received either HD or PD during follow-up, respectively, compared to patients who received a renal transplant. Conclusions. This thesis has contributed to knowledge about CVRF prevalence, longer-term survival and CVD outcomes in patients who initiated RRT in childhood by identifying high prevalence of CVRFs and that CVD is a common complication. This study did not investigate whether anaemia, hypertension, dyslipidaemia and obesity are associated with a higher risk of developing CVD after start of RRT. Future research is needed to study whether treatment of anaemia, hypertension, dyslipidaemia and controlling body weight will reduce the risk of CVD and mortality in patients who initiated RRT in childhood.
|
147 |
Farmacocinética do Meropenem infundido por 3 horas em pacientes criticamente enfermos em terapia renal substitutiva contínuaLeusin, Fabiane January 2012 (has links)
A terapia renal substitutiva contínua (TRSC) é amplamente utilizada em pacientes criticamente enfermos com insuficiência renal aguda (IRA). O meropenem é um carbapenêmico usado em pacientes críticos que tem uma atividade antibacteriana dependente do tempo. O objetivo do estudo foi avaliar a farmacocinética do meropenem infundido em três horas em pacientes submetidos à TRSC. Estudamos as concentrações plasmáticas e de efluente em cinco pacientes submetidos à TRSC. As amostras foram coletadas em momentos 0, 30 min, e 1, 2, 4, 6 e 8 horas após o início de uma infusão de 3 horas. As determinações de meropenem foram feitas por cromatografia líquida de alta eficiência. Quatro pacientes do sexo masculino e um feminino, idade de 53,0 ± 19,7 (23 a 80 anos), 62,1 ± 10,6 kg, foram estudados. Parâmetros farmacocinéticos apresentados em mediana (amplitude): concentrações plasmáticas, 34.86mg / L (10,08-139,27); tempo de meia vida (t ½), 1,8 h (1,4-3,0); volume de distribuição (Vd), 8,29 L (5,8-15,3); depuração total (Dept ) 3,98 L / h (2,51-4,35); concentração máxima (Cmax) 48,5 mg/L (37,0-105,8); concentração mínima (Cmin) 20,1 mg / L (14,0-16,6); constante de eliminação (Kel), 0,38 (0,34-0,43); área sob a curva de concentração versus tempo (AUC 0 a 8 h), 251,1 mg / Lh (229,7-398,4); (AUC de 0a∞), 275,1 mg /Lh (263,8-453,6).A depuração total pela TRSC variou de 8,46 a 18,33 ml/min. No efluente as concentrações máximas foram 24,35 e 74,81 mg /L. A eliminação de meropenem por TRSC é semelhante ao que é relatado pelo rim normal, quando é infundido por 3 horas a cada 8 h. Os níveis plasmáticos foram sempre acima do MIC necessário. Podemos concluir que não houve necessidade de ajuste de dose do meropenem com a dose de TRSC prescrita. / Continuous renal replacement therapy (CRRT) is widely used in critically ill patients with acute kidney injury (AKI). Meropenem is a carbapenem used in critically ill patients, which has a time dependent antibacterial activity. The aim of the study was to assess the pharmacokinetics of meropenem on a 3-hour infusion in patients undergoing CRRT due to AKI. We studied the plasmatic and effluent concentrations in five patients undergoing CRRT. The samples were collected at moments 0, 30 minutes, and 1, 2, 4, 6 and 8 hours after the beginning of the 3-hour infusion. The meropenem determinations were made through high performace efficiency liquid chromatography (HPLC). Four male patients and one female patient, with a mean age of 53,0 ± 19,7 (23 to 80 years), weighing 62,1 ± 10,6 kgs were studied. Pharmacokinetic parameters presented in medians (range): plasmatic concentrations, 34.86mg / L (10,08-139,27); half-life (t ½), 1,8 h (1,4-3,0); volume of distribution (Vd), 8,29 L (5,8-15,3); total clearance (CLT) 3,98 L / h (2,51-4,35); (Cmax) (maximum plasma concentration), 48,5 mg / L (37,0-105,8); Cmin (minimum plasma concentration)20,1 mg / L (14,0-16,6); elimination constant (Kel), 0,38 (0,34-0,43); area under the concentration versus time curve (AUC 0 a 8 h), 251,1 mg / Lh (229,7-398,4); (AUC 0 a ∞) 275,1 mg / Lh (263,8-453,6). In the effluent, the maximum concentrations varied from 24,35 to 74,81 mg/L, and the clearance from the therapy varied from 8,46 to 18,33 ml/min. The elimination of meropenem through CRRT is similar to that of a normal kidney, given a 3-hour infusion every 8 hours. Plasmatic levels were always above the necessary MICs. We can conclude there was no need for dose adjustment of meropenem with the prescribed CRRT dose.
|
148 |
Avaliação da função tubular renal de pacientes sobreviventes de insuficiência renal aguda severa submetidos à diáliseChiella, Bianca Paula Mentz January 2012 (has links)
Introdução: Em torno de 30 a 50% dos pacientes críticos desenvolvem insuficiência renal aguda (IRA), sendo que sua progressão leva à necessidade de terapia renal substitutiva (TRS). Dentre os sobreviventes, em torno de 15 a 23% possuem a necessidade de diálise após alta. A ocorrência da insuficiência renal aguda tem sido associada à futura progressão para doença renal crônica. É possível que marcadores tubulares estejam alterados após a recuperação da IRA, antecipando o desenvolvimento de doença renal crônica. Objetivos: Comparar a β2 Microglobulina, as enzimas urinárias N-acetil- β-D-glucosaminidase, lactato desidrogenase e fosfatase alcalina, as frações de excreção de magnésio, fósforo, potássio e ácido úrico e o gradiente transtubular de potássio, bem como a presença de microalbuminúria e proteinúria entre pacientes normais sem qualquer história prévia de dano ou qualquer tipo de disfunção renal, com pacientes sobreviventes de IRA severa com necessidade de hemodiálise que recuperaram função renal de forma a avaliar se existem diferenças entre os 2 grupos. Métodos: Foram incluídos pacientes que apresentaram insuficiência renal aguda com necessidade de hemodiálise internados no centro de terapia intensiva (CTI) do Hospital de Clínicas de Porto Alegre e que receberam alta nos períodos de 2007 a 2010, sem apresentar as seguintes co-morbidades: insuficiência renal crônica, hepatopatia crônica, pacientes HIV positivo, transplantados, doença vascular severa, diabetes com complicações crônicas e rim único funcionante e que apresentavam função renal normal definida por taxa de filtração glomerular > 60 mL/min/1.73m2 calculada pela equação CKD-EPI. Os mesmos foram comparados com voluntários sadios pareados por sexo e idade (+/- 4 anos). Para avaliação das frações de excreção e do gradiente transtubular de potássio foram feitas análises excluindo o uso de medicamentos diuréticos, inibidores da ECA e bloqueadores dos receptores de angiotensina. Resultados: A fração de excreção de magnésio encontrou-se aumentada no grupo com IRA prévia seguida por um menor gradiente transtubular de potássio bem como lactato desidrogenase elevada. O grupo com IRA prévia apresentou proteinúria e microalbuminúria e embora sem significância estatística (P=0,052) uma maior fração de excreção de fósforo. Conclusão: Mesmo com taxa de filtração glomerular normal comparável, os sujeitos do grupo com ira prévia apresentaram sugestivas alterações em nível tubular refletidas por maior fração de excreção de magnésio, elevada lactato desidrogenase e um menor gradiente transtubular de potássio, microalbuminúria e proteinúria que refletem um possível dano renal. Estes achados levam à hipótese de que sujeitos com prévia IRA severa com necessidade de terapia de renal substitutiva, apresentam uma possível sequela relativa à IRA prévia ou uma predisposição para insuficiência renal crônica. / Background: About 30 to 50% of the critically ill patients develop acute renal failure (ARF) and the progression leads to the need of renal replacement therapy. Between the survivors 15 to 23% has the need of dialysis after discharge. The severity of the ARF is a robust predictor for the development of a future chronic kidney disease. The occurrence of acute renal failure has been associated with future progression of chronic kidney disease. Objective: Compare β2-microglobulin, the urinary enzymes N-acetyl-β- D-glucosaminidase, lactate dehydrogenase, alkaline phosphatase fractional excretion of magnesium, phosphorous, potassium and uric acid transtubular potassium gradient, including the presence of microalbuminuria and proteinuria between subjects with normal renal function without any previous history of acute renal injury or any kind of renal dysfunction with survivors of severe ARF with the needed of hemodialysis that recovered renal function in order to evaluate if there are differences between the 2 groups. Methods: It was enrolled patients that presented acute renal failure with the need of hemodialysis hospitalized on intensive care unit (ICU) and discharged on the period of 2007 to 2010 at Hospital de Clínicas de Porto Alegre, without the following co-morbidities chronic renal failure, chronic hepatopathy, positive HIV, transplants, severe vascular disease, diabetes with chronic complications and single functioning kidney that presented normal renal function defined as glomerular filtration rate (GFR) > 60 mL/min/1.73m2 calculated by CKD EPI formula The subjects were compared with healthy volunteers and paired by sex and age (+/- 4 years). To evaluate fractional excretions and transtubular potassium gradient, analyses were made excluding subjects that were taken diuretic medication, ACE inhibitors and angiotensin block receptors. Results: The fractional excretion of magnesium was finding increased on the previous ARF group followed by a lower transtubular potassium gradient and elevated lactate dehydrogenase. The previous ARF group showed proteinuria and microalbuminuria and although without statistical significance (p=0.052) an elevated phosphorous excretion. Conclusion: Although normal glomerular filtration rate, the subjects with previous ARF, showed suggested tubular alterations reflected by a higher fractional excretion of magnesium, elevated lactate dehydrogenase and a lower transtubular potassium gradient, microalbuminuria and proteinuria that reflects a possible renal damage. Those findings lead to the hypothesis that subjects with previous severe ARF with the need of renal replacement therapy present a possible sequel related to previous ARF or a predisposition to chronic kidney disease.
|
149 |
Monitoramento da doença renal crônica terminal pela autorização de procedimentos de alta complexidade - APAC - Brasil 2000 a 2006Moura, Lenildo de January 2007 (has links)
Objetivos: Descrever o perfil epidemiológico dos pacientes em Terapia Renal Substitutiva (TRS) no período de 2000 a 2006 a partir do subsistema de Autorização de Procedimentos de Alta Complexidade em Terapia Renal Substitutiva – APAC/TRS e avaliar o potencial desse sistema para a vigilância e o monitoramento da Doença Renal Crônica Terminal no Brasil. Metodologia: Este estudo constituiu-se na descrição da Doença Renal Crônica e APAC/TRS por meio da análise dos instrumentos normativos e outros documentos técnico– administrativos e análise do perfil epidemiológico dos pacientes no período de 2000 a 2006. Resultados: No período, 148.284 pacientes iniciaram procedimentos de diálise e hemodiálise, destes 57% eram do gênero masculino. A incidência relativa foi maior em homens que em mulheres e aumentou com a idade, mas nas mulheres o pico ocorreu na faixa etária de 65 a 74 anos. A incidência global anual foi de 119,8/1.000.000 habitantes para todo Brasil, variando de 143,6/1.000.000 na região sul a 66,3/1.000.000 na região norte e se mantendo estável no período. Hipertensão foi causa da insuficiência renal em 32.571 (22,0%), diabetes mellitus em 20.412 (13,8%) e glomerulonefrites em 10.654 (7,2%) casos, sendo 66.439 (44,8%) casos de causa incerta. Conclusão: A APAC/TRS apresenta limitações inerentes a bancos de dados administrativos, com lacunas a serem preenchidas. Mesmo assim, recomenda-se sua utilização para subsidiar ações de promoção, prevenção, assistência da doença renal crônica terminal , elaboração de indicadores e fomento de estudos epidemiológicos e econômicos. / Objectives: Describe the subsystem Authorization of Procedures of High Complexity in Therapy Renal Substitutiva - APAC TRS, the epidemiological profile of the patients in the period 2000 to 2006 and evaluate its potential as one of the tools to support the monitoring and tracking of Chronic Renal Disease. Methodology: This study’s objective is to describe the Authorization of High Complexity Procedures for Renal Replacement Therapy database, and evaluate its potential for surveillance of chronic renal disease through analysis of the epidemiologic profile of incident cases of dialysis. APAC datafiles were aggregated and verified for inconsistencies and duplicities. Incident cases were described according to age, gender, region of the country, and underlying cause of renal disease. Results: From 2000 to 2006, 148.284 patients initiated dialysis, 57% being men. The relative incidence is higher in men than in women and increases monotonically with age, although the peak in women occurs in the age bracket of 65 to 74 years. The overall annual incidence was 119,8/1,000,000 habitants, varying from 143,6/1,000,000 in southern Brazil to 66,3/1,000,000 in the northern region, and maintaining stability over the period. Hypertension was listed as cause of renal disease in 32.571 (22,0%), diabetes mellitus in 20.412 (13.4%) and glomerulonephritis in 10.654 (7,2%), with 66.439 (44,8%) cases having no determined cause. Conclusion: The APAC/TRS system presents limitations inherent to administrative databases, with gaps requiring attention. Nevertheless, these data demonstrate its potential to support public health measures for chronic renal disease, including the elaboration of health indicators and to stimulate epidemiologic and economic studies.
|
150 |
Aspectos farmacoeconômicos associados à terapia de reposição enzimática para mucopolissacaridoses tipo I, II e VI : um estudo com ênfase em intervenções médicasBitencourt, Fernanda Hendges de January 2013 (has links)
Introdução: As mucopolisaccaridoses tipo I (MPS I), tipo II (MPS II) e tipo VI (MPS VI) são doenças lisossômicas (DL) para as quais está disponível a terapia de reposição enzimática (TRE) com laronidase, idursulfase e galsufase, respectivamente. Objetivo Primário: Analisar a frequência anual de intervenções médicas (número de consultas, internações, cirurgias, exames solicitados, medicamentos prescritos, equipamentos de uso crônico e outras formas de terapia) em uma amostra de pacientes brasileiros com MPS I, II e VI e, desta forma, contribuir para o conhecimento dos aspectos farmacoeconômicos relacionados a essas doenças. Metodologia: Estudo exploratório, retrospectivo, de base hospitalar, baseado em revisão de prontuário, com amostragem por conveniência, e que foi realizado em duas etapas (etapas 1 e 2). Um instrumento específico para a coleta de dados de ambas as etapas foi construído pela equipe do estudo, que é multidisciplinar. Os desfechos de interesse foram as frequências anuais de intervenções médicas (consultas, exames, cirurgias, internações, medicamentos utilizados, outras formas de terapia). A etapa 1 consistiu em estudo pré-experimental, realizado no Serviço de Genética Médica do Hospital de Clínicas de Porto Alegre (SGM-HCPA), e que comparou as variáveis de interesse, para o mesmo grupo de pacientes, entre o período pré e pós-TRE. Os critérios de inclusão dessa etapa foram: ter diagnóstico confirmado de MPS I; estar em acompanhamento regular no SGM-HCPA desde o diagnóstico; estar em TRE por pelo menos um ano; e não ter participado de ensaio clínico envolvendo TRE ou ter realizado transplante de células-tronco hematopoiéticas. A etapa 2 foi transversal, multicêntrica (centros incluídos: SGMHCPA, Departamento de Genética Médica da Universidade Estadual de Campinas - UNICAMP, Pontifícia Universidade Católica de Campinas – PUC-Campinas, e Departamento de Pediatria da Universidade Estadual do Rio de Janeiro - UERJ), e comparou as variáveis de interesse entre grupos diferentes de pacientes (aqueles recebendo TRE e aqueles não recebendo TRE). Para essa etapa, foram considerados somente os dados relativos a 2010, sendo os seguintes os critérios de inclusão dos pacientes: ter diagnóstico confirmado de MPS I, II e VI; não estar participando de nenhum ensaio clínico envolvendo TRE ou ter realizado transplante de células-tronco hematopoiéticas; estar em TRE por pelo menos 12 meses antes do início da coleta, ou em acompanhamento por pelo 12 meses antes do início da coleta. Resultados: Etapa 1 - Nove pacientes (graves=3; atenuados=6) com MPS I foram incluídos no estudo, com mediana de idade de diagnóstico de 4,4 anos. Somente o número de cirurgias/ano/paciente foi dependente do tempo de doença (p=0,0004) e da gravidade do fenótipo (p=0,014). Com relação às comparações pré e pós-TRE, as variáveis que apresentaram diferença significativa (média do número/ano/paciente) foram: exames (pré-TRE=10,2+2,7; pós-TRE=22,5+2,1; p=0,005) e internações (pré-TRE=0,05+0,04; pós-TRE=0,30+0,11; p=0,013). Para as demais variáveis, não foi encontrada associação. Etapa 2 - Trinta e quatro pacientes com MPS I (n=12), II (n=17) e VI (n=5) foram incluídos no estudo. Desses, sete não utilizavam TRE (grupo “sem TRE") e 27 faziam uso de tratamento específico (grupo “com TRE"). Não foi encontrada correlação significativa entre tempo de doença e as variáveis estudadas. Considerando a amostra total, foi encontrada diferença entre o grupo “sem TRE” e o grupo “com TRE” em relação à mediana de internações hospitalares e de cirurgias realizadas [1(0-2) vs. 0 (0-1), p=0,015; e 0 (0-2) vs. 0 (0-0), p=0,040, respectivamente]. Para as crianças/adolescentes (<18 anos), não foi encontrada diferença estatística entre os grupos. Os pacientes com comprometimento cognitivo utilizavam mais medicamentos que os demais (p=0,024). Encontrou-se correlação negativa entre as variáveis duração da TRE e número anual de internações (r= -0,504; p=0,007). Discussão/ Conclusões: Este é um dos primeiros estudos a avaliar aspectos relacionados à farmaconomia da TRE para as MPS. De acordo com os resultados obtidos na etapa 2, verifica-se que, desconsiderando-se o custo associado às infusões, o custo do tratamento de pacientes com MPS parece ser menor para aqueles pacientes que utilizam a TRE do que para os pacientes que fazem somente tratamento sintomático. Entretanto, de acordo com a etapa 1 do estudo, a TRE parece não impedir a evolução da doença, pelo menos em relação à MPS I, e, assim, a cada ano de vida do paciente ocorreria um incremento do custo associado ao tratamento. Estudos adicionais, com maior tamanho amostral, deverão ser realizados para confirmar nossos achados. / Introduction: The mucopolysaccharidoses type I (MPS I), II (MPS II) and VI (MPS VI) are lysosomal disorders (LSD) for which enzyme replacement therapy (ERT) with laronidase, idursulfase and galsulfase, respectively, are available. Principal objective: To analyze the annual frequency of medical interventions (number of medical appointments, hospital admissions, surgical procedures, exams performed, medications prescribed, ancillary therapies and the use of medical devices) in a sample of Brazilian patients with MPS I, II and VI, and thus, contribute to the understanding of some pharmacoeconomic aspects related to these diseases. Methodology: Retrospective, exploratory, hospital-based study, based on medical records review, with convenience sampling, which was conducted in two steps (steps 1 and 2). A specific data collection instrument for both steps was designed by the study team, which is multidisciplinary. The chosen outcomes were: annual frequencies of medical interventions (medical appointments, exams, surgical procedures, hospital admissions, medications used and ancillary therapies). Step 1 was a pre-experimental study conducted at the Medical Genetics Service of Hospital de Clínicas de Porto Alegre (SGM-HCPA), and compared the variables of interest between the pre and post-ERT periods for the same group of patients. The patient inclusion criteria were: a biochemical diagnosis of MPS I and regular follow-up at SGM-HCPA since diagnosis; ERT for at least 1 year; no enrollment in any clinical trials involving ERT, and no history of hematopoietic stem cell transplantation. Step 2 was a cross-sectional and multicentric estudy (Centers included: SGM-HCPA), the Department of Medical Genetics of Universidade Estadual de Campinas - UNICAMP, Pontifícia Universidade Católica de Campinas - PUC-Campinas, and the Department of Pediatrics at Universidade Estadual do Rio de Janeiro – UERJ, which compared the variables of interest between different groups of patients (those receiving and those not receiving ERT). For this step only data from 2010 were considered. The inclusion patient criteria were: a biochemical diagnosis of MPS I, II or VI; no enrollment in any clinical trials involving ERT, and no history of hematopoietic stem cell transplantation, to be on ERT for at least 12 months before the start of data collection or to undergo regular follow-up for at least 12 months before the start of data collection. Results: Step 1 – Nine MPS I patients (severe=3; attenuated phenotype=6) were included in the study with median age at diagnosis was 4.4 years. Only the number/year/patient of surgeries was found to be dependent on length of disease (p=0.0004) and on severity of phenotype (p=0.014). Regarding pre- and post-ERT comparisons, the variables for which a significant difference was detected (mean number/year/patient) were exams (pre-ERT, 10.2±2.7; post-ERT, 22.5±2.1; p=0.005) and hospital admissions (pre-ERT, 0.05±0.04; post-ERT, 0.30±0.11; p=0.013). For the other variables, no association was found. Step 2: Thirty-four patients with MPS I, II and VI were included (I=12, II=17, VI=5). From them, 27 on ERT (“ERT group”) and 7 receiving supportive care only (“non-ERT group”). There were no significant correlation between length of disease and any of the variables of interest. There were significant between-group differences in the median number of hospital admissions and surgical procedures, both of which were higher in the non-ERT group [1(0-2) vs. 0 (0-1), p=0,015; e 0 (0-2) vs. 0 (0-0), p=0,040, respectively]. There were no significant between-group differences when only children and adolescents (<18 years) were taken into account. Patients with cognitive involvement used more medications than the others (p=0.024). A correlation was detected between time on ERT and the hospital admissions variable (r= -0.504; p=0.007). Discussion/conclusions: This was one of the first studies to evaluate aspects related to pharmacoeconomics of ERT for MPS. According to the results of step 2, and not acknowledging the costs associated with recombinant enzyme infusions, patients with MPS who undergo ERT generate less cost to SUS than patients on symptomatic treatment. On the other hand, according to the results of step 1, ERT seems not to stop the disease progress, at least in respect to MPS I, and thus, for each year of a patient life occurred an increase in cost associated with treatment. Additional studies with larger sample size are needed to confirm our findings.
|
Page generated in 0.0704 seconds